Phase IIa BPL-003 monotherapy study in patients with TRD
We completed the placebo-controlled phase of our single ascending dose study of BPL-003 (our intranasal formulation of 5-MeO-DMT) in healthy volunteers in November 2022 and we are now conducting a Phase IIa open-label study of BPL-003 in patients with Treatment Resistant Depression (TRD). The study (NCT05660642) is taking place at King’s College Hospital and Hammersmith Medicines Research (HMR) in London, and will involve patients with moderate to severe symptoms who have not shown an adequate response to prior standard antidepressant medication. The study will evaluate the safety and efficacy of a single dose of BPL-003 alongside psychological support.
Phase I ELE -101 Studies in Healthy Volunteers
We are conducting a Phase I study of ELE -101 in healthy volunteers in Manchester and Liverpool. This is a Phase I, double-blind, placebo-controlled, randomised single ascending dose study to assess the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) and subjective drug intensity (SDI) of intravenous (IV) doses of ELE-101 in healthy male and female adult participants.
Investigator Initiated Studies
We are committed to understanding the therapeutic potential of psychedelic drugs and support rigorous investigator-initiated research advancing psychedelic science.
We work in collaboration with select academic institutions and researchers.
For general information about our ongoing research activities, please use the contact form on our website or email us on medinfo@beckleypsytech.com
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
